OXFORD, UK; 4th February 2026 – The canine cancer vaccine company, CaniVax, today announced that it had secured significant investment from a group of established investors and entrepreneurs. The funding will enable CaniVax to advance its lead cancer vaccine towards veterinary clinical studies, and reach a series of critical scientific, regulatory and commercial milestones.
Announcing the investment, CaniVax Chairman James Noble commented “We are delighted to have secured investment from such a seasoned group of investors, which underscores strong confidence in the attractive commercial opportunity that CaniVax offers. It is an exciting time for our company, which aims to provide dog owners and veterinary professionals new vaccines for treating canine cancer.”
CaniVax’s COO commented “This investment enables us to progress our lead vaccine programme towards clinical readiness. We are generating robust, decision-important results to support our clinical development plan and to position the company well for the next phase of growth.”
Background on CaniVax:
CaniVax is a veterinary biopharma company developing a new type of pathology-specific cancer vaccine engineered to treat canine cancer. CaniVax uses proprietary platforms built on multi-omics gene and protein expression technologies, complemented by deep-learning algorithms, to identify highly immunogenic cancer antigens. The company’s vaccination strategy educates the dog’s natural immunity to recognise and destroy tumour cells. The company is located in Oxford, UK.
Background on canine cancer:
Approximately 1 in 4 dogs will develop cancer at some point in their life, with risk increasing significantly with age. In the United States, estimates indicate that around 6 million dogs are diagnosed with cancer each year, illustrating the scale of the disease burden in one of the world’s largest companion-animal healthcare markets. Common types of canine cancer include melanoma, hemangiosarcoma, mast cell tumours and lymphoma. Despite advances in veterinary care, many canine cancers remain clinically unmet.
The veterinary oncology market is experiencing substantial growth, supported by rising cancer prevalence in aging pet populations and increased expenditure on pet healthcare. Industry estimates place the global veterinary oncology market in the low-to-mid billions of US dollars in the mid-2020s, with continued expansion expected. North America represents the largest regional share of this market and Europe is a significant component, with sustained growth expected across major territories including the UK, Germany and France.
Download the Press Release here
For further information contact:
See: www.canivax.com/news